ARTICLE | Company News

Optimer, Astellas deal

April 2, 2012 7:00 AM UTC

Optimer granted Astellas exclusive rights in Japan to develop and commercialize antibiotic fidaxomicin. Optimer will receive $20 million up front and is eligible for up to an additional $70 million in milestones. Optimer could also receive payments representing a double-digit percent of net sales in Japan. ...